Claims for Patent: 9,750,713

Summary for Patent: 9,750,713

Title:	Compositions and methods of use of phorbol esters
Abstract:	Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson\'s disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
Inventor(s):	Chen; Hung-Fong (Taipei, TW), Han; Zheng Tao (Zhengzhou, CN)
Assignee:	Biosuccess Biotech Co. Ltd. (Santa Clara, CA)
Application Number:	15/154,100
Patent Claims:	1. A method for alleviating or treating one or more side effects of radiation comprising administering to a mammalian subject in need thereof, an effective amount of phorbol ester of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, or polymorph thereof to said mammalian subject to alleviate or treat one or more side effects due to radiation ##STR00021## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen, hydroxyl, ##STR00022## R.sub.3 is hydrogen, and ##STR00023## 2. The method of claim 1, wherein R.sub.1 or R.sub.2 is ##STR00024## the remaining R.sub.1 or R.sub.2 is ##STR00025## and R.sub.3 is hydrogen. 3. The method of claim 1, wherein the phorbol ester is phorbol 13-butyrate, phorbol 12-decanoate, phorbol 13-decanoate, phorbol 12,13-diacetate, phorbol 13,20-diacetate, phorbol 12,13-dibenzoate, phorbol 12,13-dibutyrate, phorbol 12,13-didecanoate, phorbol 12,13-dihexanoate, phorbol 12,13-dipropionate, phorbol 12-myristate, phorbol 13-myristate, phorbol 12,13,20-triacetate, 12-deoxyphorbol 13-angelate, 12-deoxyphorbol 13-angelate 20-acetate, 12-deoxyphorbol 13-isobutyrate, 12-deoxyphorbol 13-isobutyrate-20-acetate, 12-deoxyphorbol 13-phenylacetate, 12-deoxyphorbol 13-phenylacetate 20-acetate, 12-deoxyphorbol 13-tetradecanoate, phorbol 12-tigliate 13-decanoate, 12-deoxyphorbol 13-acetate, phorbol 12-acetate, or phorbol 13-acetate. 4. The method of claim 1, further comprising administering at least one secondary or adjunctive therapeutic agent. 5. The method of claim 4, wherein the at least one secondary or adjunctive therapeutic agent is administered to said subject in a coordinate administration protocol, simultaneously with, prior to, or after, administration of said phorbol ester to said subject. 6. The method of claim 5, wherein the at least one secondary or adjunctive therapeutic agent is selected from the group consisting of steroids, amifostine, chlorhexidine, benzydamine, sucralfate, KGF, palifermin, Cu/Zn superoxide dismutase, Interleukin 11 , or prostaglandins. 7. The method of claim 1, wherein the one or more side effects of radiation therapy are moist desquamation, soreness, diarrhea, nausea, vomiting, appetite loss, constipation, itchy skin, peeling, mouth and throat sores, edema, infertility, fibrosis, epilation, or mucosal dryness. 8. The method of claim 1, wherein said effective amount comprises between about 10 .mu.g and about 1500 .mu.g of said phorbol ester or derivative compound of Formula I every day. 9. The method of claim 1, wherein said effective amount comprises between about 125 .mu.g to about 500 .mu.g of said phorbol ester or derivative compound of Formula I every day.

Details for Patent 9,750,713

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	KEPIVANCE	palifermin	For Injection	125103	12/15/2004		2027-01-31